NEW YORK, March 23 – Vincent Kazmer said Friday he was resigning as chief financial officer of NetGenics to join Phase-1 Molecular Toxicology as CEO.

“Phase-1 is a good opportunity,” Kazmer said. His resignation is effective immediately and he will start work at Phase-1 Molecular Toxicology in April.

The company, which is based in Santa Fe, NM, uses gene expression technologies and bioinformatics to help improve lead optimization and diminish toxic effects early in a drug’s development.

Phase-1’s founder Spencer Farr will head the company’s R&D division.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.